Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

Dec 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (4346)	7/25/2001 2:57:34 PM
From: Biomaven	Read Replies (2) of 52153

tuck, Recent AC favorable meetings haven't produced much in the way of upward bounces. OTOH, they've mainly been for products (like Natrecor) where approval was pretty much in the stock price already. Here there is still some uncertainty. Unfortunately the posted briefing documents I could find today don't contain some of the key FDA goodies like the statisticians' report. There is some muttering in the FDA briefing about lack of active monitoring for adverse events in some trials, but mostly I didn't see anything that worried me on a super quick scan. A negative view by the AC would likely cut the stock price in half, depending on just what the problem was. Straddles around the times of these meetings are mighty expensive - I'll be interested to learn how you do on yours. Personally I'm just holding the stock long and hoping for a favorable meeting. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next